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The wealth of bioactivity information now available on low-molecular weight compounds
has enabled a paradigm shift in chemical biology and early phase drug discovery
efforts. Traditionally chemical libraries have been most commonly employed in screening
approaches where a bioassay is used to characterize a chemical library in a random search
for active samples. However, robust curating of bioassay data, establishment of ontologies
enabling mining of large chemical biology datasets, and a wealth of public chemical
biology information has made possible the establishment of highly annotated compound
collections. Such annotated chemical libraries can now be used to build a pathway/target
hypothesis and have led to a new view where chemical libraries are used to characterize
a bioassay. In this article we discuss the types of compounds in these annotated libraries
composed of tools, probes, and drugs. As well, we provide rationale and a few examples
for how such libraries can enable phenotypic/forward chemical genomic approaches. As
with any approach, there are several pitfalls that need to be considered and we also outline
some strategies to avoid these.
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INTRODUCTION
Chemical libraries employed for drug discovery ideally con-
tain biologically active chemical scaffolds which are synthetically
tractable. Both historically and today compounds are chosen to
populate chemical libraries based on ease of synthesis and avail-
ability and over time a wealth of information on the bioactivity of
these libraries has been collected. For instance, the original com-
pound collections of companies such as Ciba Geigy and Bayer
arose out of the dye industry. Repurposing dyes for drug devel-
opment was a common practice and successful in identifying
the first chemotherapeutics (Hager, 2006). Further exploration
of dyes composed of quinazolone-3-oxides led to the chance
discovery of chlordiazepoxide (Librium®, an anticonvulsant and
anxiolytic drug) as one of the first benzodiazepines (Sternbach,
1979). As more high-throughput chemistry approaches became
available, compound libraries were designed based on biologi-
cally active pharmacophores such as 1,4-benzodiazepin-2-ones
and purines providing libraries that are broadly active against
a variety of receptors and target classes (Guo and Hobbs, 2003;
Dolle et al., 2006). In 1988 Evans and co-workers at Merck coined
the term “privileged” structure to recognize the high bioactivity
of such compounds and assembling libraries based on privileged
scaffolds represents an early use of biological compound annota-
tion to design biology-orientated chemical libraries (Evans et al.,
1988). Another example of exploring annotated compound infor-
mation which has been now applied is the so-called “rule of 5”
(Ro5). Through examining route of administration data pertain-
ing to known drugs available from the World Drug Index (WDI),
the physicochemical characteristics of well-absorbed drugs were
defined based on four parameters: molecular weight (MW),
lipophilicity (measured by the partition coefficient logP), hydro-
gen bond donors, and hydrogen bond acceptors. The Ro5 is based
on the fact that all values are multiples of 5 and led to the term
“drug-likeness” when characterizing and designing compounds
and libraries.
Modern libraries are typically a collection of historical
archives, contributions from drug discovery programs (which
may add thousands of related analogs as well as clinical candi-
dates), and commercial sources that can include both purified
natural products and combinatorial collections. Natural product
inspired libraries (Basu et al., 2011; Zimmermann et al., 2013),
or methods such as diversity oriented synthesis (Nielsen and
Schreiber, 2008) which attempt to expand the composition of cur-
rent libraries to new areas of chemical property space have also
been pursued. At Novartis, fractionated natural product extracts
continue to play a key role in discovery efforts. Alternatively, com-
binatorial collections have been constructed where thousands of
slight variations are made around a central scaffold in an attempt
to densely cover structure-activity relationships (SAR) within
a narrow region of chemical property space (Sanchez-Martin
et al., 2004). Overtime, a significant amount of bioassay data has
accumulated on compound libraries leading to both private and
public databases that provide an archeological footprint of past
discovery efforts. These databases can be configured to provide
a rich source of small molecule bioactivity data to drive future
discovery efforts. Here we provide examples of how this informa-
tion can be used to design libraries composed of chemical tools,
probes, and drugs. Definitions and examples are given for various
types of compounds and libraries. We also outline some of the
issues involved with applying annotated compound libraries.
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CATEGORIES OF COMPOUNDS EMPLOYED IN FOCUS
LIBRARIES
Compounds that have been applied to biological systems can be
classified as tools, probes, or drugs (Figure 1). Tool compounds
can be broadly applied to understand general biological mech-
anisms. Examples include cycloheximide (Figure 1), a natural
product adopted by cell biologists as a means to study transla-
tional mechanisms. Cycloheximide is too toxic for in vivo studies
but is widely applied to in vitro cell-based assays. Some com-
pounds such as ActinomycinD (Figure 1), a natural product from
bacteria that inhibits the function of RNA polymerase, is both
a chemotherapeutic and a tool compound used to test for tran-
scriptional mechanisms. Similarly doxycycline (Figure 1) is used
both as an antibacterial drug and as a tool to develop inducible
cell-based assays using the tetracycline repressor system (Gossen
and Bujard, 1992). The natural product forskolin (Figure 1),
and its water-soluble analogs (Laurenza et al., 1987), stimulates
adenylate cyclase serving as a critical tool compound to study
and develop assays for Gαi/Gαs coupled GPCRs. Such compounds
have an essential role in the cell-biologist’s tool box.
Employing compounds to probe complex biological pathways
has its roots in the discipline of bioorganic chemistry. Konard
Bloch’s use of deuterated acetate to investigate the biosynthesis
of cholesterol, described in 1942 (Bloch and Rittenberg, 1942),
could be attributed to an early use of a chemical probe. However,
modern chemical probes have primarily been discovered through
high-throughput screening (HTS) efforts. Chemical probes as
applied to in vitro assay systems may have a more limited appli-
cation compared to tool compounds as these are specifically
designed to modulate an isolated target protein or signaling path-
way. General guidelines for what constitutes an optimal chemical
probe will depend on the application and context of interest
but includes chemical properties related to stability, solubility,
availability, and cell permeability, as well as the potency and
selectivity of the compound (Frye, 2010; Workman and Collins,
2010). Some of the first initiatives in probe discovery were at the
Harvard Institute of Chemistry and Cell Biology (ICCB) founded
by Mitchison and Schreiber in 1998 where chemical approaches
and biological disciplines were merged and organized into a new
area of research (Hager, 2006; Huang et al., 2011). In 2003 the
US National Institutes of Health (NIH) started the Molecular
Libraries Initiative (MLI) to provide industrial-scale HTS tech-
nologies and chemical probes for basic research (Lipinski et al.,
1997; Klekota and Roth, 2008). Through this effort many young
investigators have been successfully trained in the methods of
compound discovery and >300 reports describing new chemi-
cal probes have been published1. There are now several initia-
tives in chemical biology in both the United States and Europe.
Guidelines for chemical probe designation have been suggested2
1 http://www.ncbi.nlm.nih.gov/books/NBK47352/
2 https://commonfund.nih.gov/molecularlibraries/index
FIGURE 1 | Small molecules as tools, probes, and drugs. The
top bar lists some general features of compounds used as tools,
probes, and drugs and example compounds are listed underneath.
Color dots designate the primary use of the compounds as a
tool (blue), probe (orange), or drug (green). β2-AR, β2-adrenergic
receptor; GSH, glutathione S-transferase; CLL, chronic lymphocytic
leukemia; ED, erectile dysfunction; PAH, pulmonary arterial
hypertension.
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which includes the demonstration of SARs wherein both active
and inactive analogs of a chemical series are identified.
Some example chemical probes are shown in Figure 1.
Trapoxin, isolated from the fungus Helicoma ambiens, is a com-
pound that naturally contains an epoxide group and was initially
characterized as a cell cycle inhibitor capable of inhibiting his-
tone deacetylation in cell lysates. The trapoxin analog K-trap
(Figure 1; Taunton et al., 1996a) allowed coupling to a solid sup-
port which identified the molecular target as a protein with high
homology to transcriptional repressors (Taunton et al., 1996b)
and resulted in the characterization of the class of enzymes known
as histone deacetylases (HDACs). The allostericMEK1/2 inhibitor
PD0325901 (Figure 1) shows good selectivity against other pro-
tein kinases and has been used as probe for this kinase in both
in vitro and in vivo assays (Ohren et al., 2004; Bain et al., 2007).
One of the grand challenges of chemical biology is to provide
chemical probes for every protein expressed from all human
genes. Some chemical probes have been successfully developed
toward new target classes such as the lysine methyltransferase
inhibitor UNC0638 (Figure 1; Vedadi et al., 2011), providing a
means to explore the function of this enzyme in model systems.
In another recent example, chemical probes have been identi-
fied with novel mechanisms such as ML285 (Figure 1) which is
an activator of the M2 isoform of pyruvate kinase, expressed in
cancer cells, and has been used as probe to study the Warburg
effect in cancer cells and animal models (Brimacombe et al., 2010;
Anastasiou et al., 2011).
Drugs are the most widely recognized small molecules due
to their beneficial pharmacological effects. Only a few thou-
sand compounds have been approved as drugs by the FDA since
1950 (Munos, 2009, 2013). Drugs are indeed the exception in
small molecule research largely due to the strict requirements
of bioavailability, low toxicity, and metabolic stability that con-
strains the properties of compounds intended to be approved
as drugs (Figure 1). The physicochemical properties of drugs
include modifications aimed at improving the absorption, distri-
bution, metabolism, and excretion (ADME) properties for in vivo
use but such properties are often irrelevant or even a hindrance
to chemical probes aimed at in vitro studies. ADME properties
are often engineered into drugs at the expense of potency, a prop-
erty more important to chemical probes, and therefore drugs are
sometimes not useful as chemical probes. In the extreme example
of a prodrug, the compound is inert until placed in vivo where
metabolism releases the active component. For example, the drug
Bambuterol (Figure 1) has been protected with carbamate moi-
eties to provide a slow-acting form of the β2-adrenoreceptor
agonist Terbutalin through the action of butyrlycholinesterase
(Huttunen et al., 2011). Ethacrynic acid (Figure 1) is a drug which
acts as a diuretic through inhibition of Na-K-Cl cotransporters
and contains a Michael acceptor which inhibits the enzyme
glutathione-S-transferase via a covalent mechanism. Such reac-
tive compounds may be less useful as chemical probes due to
instability and promiscuity in an in vitro setting. On the other
hand, drugs such as the chemotherapeutic Fludarabine phosphate
(Figure 1), acting through general inhibition of DNA synthesis,
may serve as useful tool compounds while drugs such as Sildenafil
(Figure 1) with a specific target (phosphodiesterase; PDE) can
be a useful chemical probe to test for the function of PDEs in
cell based assay systems. Other drugs cannot be used as tools or
probes because they have an undefined or complex mechanism
of action. For example, Modafinil is a drug marketed for wake-
fulness disorders discovered in the 1970s for which the molecular
mechanism of action remains unknown. As well, antipsychotics
often show a complex polypharmacology that is required for effi-
cacy but their mechanism is not well understood (Roth et al.,
2004; Garcia-Serna and Mestres, 2011), this is discussed further
below. Therefore, while it may be useful to study the underlying
mechanisms of drugs using chemical biology techniques, efforts
employing certain drugs to help understand the mechanisms
underlying biological activity could be challenging requiring the
combination of chemical and systems biology approaches to fully
leverage such compounds.
APPROACHES AND RATIONALE FOR LIBRARY DESIGN AND
APPLICATIONS TO PHENOTYPIC ASSAYS
The use of annotated compound collections to enhance the
understanding of the activity arising from phenotypic assays
has been practiced for more than 10 years (Root et al., 2003).
Currently, such focused libraries are playing an increasing
role when implementing either target-based or cell-based assay
approaches due to the desire to investigate new biology andmech-
anisms. Library design approaches can be thought of in three
ways (Box 1) and each of these will be described below with an
emphasis on applications to cell-based and phenotypic assays.
TARGET-ORIENTED LIBRARIES
In the era of target-based screening, much effort was dedicated
to the design of target-focused libraries, i.e., screening collections
of compounds specifically tailored to modulate a given target or
target family (Harris et al., 2011). The aim of these library design
efforts was to increase hit rates and cost-benefit ratios by screen-
ing compounds with an a priori higher likelihood of being active
Box 1 | Target-based vs. phenotypic screening libraries.
Target-oriented libraries: A focused library is built around a target or target family from known pharmacophores or privileged scaffolds.
These scaffolds are derived from historical experimental bioactivity data as well as ligand- or structure-based virtual screening approaches.
Phenotypic-oriented libraries: A maximally biologically or chemically diverse library is assembled. Special emphasis might be given to
physicochemical properties of compounds to optimize cell permeability and solubility.
Hypothesis-driven phenotypic libraries: Based on the knowledge about the biological model/pathway under study, bioinformatics and
cheminformatics resources are leveraged to link diseases, molecular processes, pathways, and functions to small molecules. Resources
are listed in Table S1.
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against the target. Depending on the amount of structural and
ligand information available for a target (or family) of interest,
various approaches for the design of such target-focused libraries
were developed and successfully applied in the past. For exam-
ple, if crystallographic structures of the target (family) of interest
are available, docking algorithms can be used to choose com-
pounds with good complementarity in electrostatics and shape
to the protein binding pocket. This strategy has been frequently
pursued for kinases (Lowrie et al., 2004; Orry et al., 2006).
By contrast, if a large number of known active ligands can be
retrieved, ligand-based design methods using molecular finger-
prints or pharmacophore models might be the method of choice,
as successfully applied to GPCRs and ligand-gated ion channels
(Lowrie et al., 2004; Harris et al., 2011). For target families such
as GPCRs, in which rich active chemical matter is available for
certain receptor classes, redesigning known ligands to show a
desired activity profile can become an engineering exercise read-
ily handled by sophisticated computer algorithms (Besnard et al.,
2012). In many cases, target-focused libraries cover only limited
structural diversity and are based around a few core (or priv-
ileged) scaffolds that are differently substituted at a number of
attachment points.
LIBRARIES FOR PHENOTYPIC SCREENS: CHEMICAL AND BIOLOGICAL
DIVERSITY
Historically, the majority of drugs have been discovered through
phenotypic drug discovery approaches where one advanced
in vivo activity in a manner agnostic of the molecular mecha-
nism of action. Both target-based and phenotypic drug discovery
approaches are practiced today with inherent advantages and
disadvantages (Swinney and Anthony, 2011). Typical modern
phenotypic assays include cell proliferation or selective growth
inhibition assays oftentimes applied within oncology or infec-
tious disease areas. Cell-based pathway–based approaches applied
to chemical library screening efforts include the wide use of
engineered cell lines in a reporter-gene assay (RGA), intracellu-
lar sensors, or high content screening approaches (Inglese et al.,
2007; Inglese and Auld, 2009). In many of these cases, a screen-
ing library covering a broad spectrum of targets and molecu-
lar processes is generally most promising. For many years, the
predominant paradigm for the assembly of such a library was
to select a chemically maximally diverse compound set using
diversity measures based on molecular scaffolds (Krier et al.,
2006), physicochemical properties, 2D and 3D chemical struc-
ture (Matter, 1997), or pharmacophore descriptors (Mason et al.,
2001). Irrespective of the specific diversity method used, all these
library design strategies followed the belief that chemical diversity
ultimately translates to biological diversity and that a chemically
diverse screening library should hence be a suitable starting point
for many different drug discovery projects. However, in many
cases, these chemically diverse sets were not truly randomly cho-
sen from chemical space given the widely accepted assumption in
medicinal chemistry that not all parts of chemical space are bio-
logically active or relevant. For example, Hert et al. (2009) have
argued that, given the size of chemical space, the odds of find-
ing a hit in a random diverse selection of ∼1 million compounds
seem rather negligible. They explain the success of HTS against
these odds by the biogenic bias of screening libraries, i.e., their
higher than average synthetic small molecule similarity to natural
products and metabolites. By default, these naturally occurring
molecules interact with biological systems and can therefore be
viewed as representatives of biologically active chemical space.
The idea of tailoring screening libraries toward biologically rel-
evant chemical space is taken to the next level by strategies that
directly integrate the known biology of compounds into screen-
ing set design by maximizing the known biodiversity instead of
the chemical diversity of screening collections. These biodiversity
methods have been made possible by the wealth of screening and
small molecule bioactivity data that has been released over recent
years in both corporate and public domains. For example, at
Novartis, two different approaches for the selection of biodiverse
screening sets have been developed (Figure 2).
The first approach uses primary activity data from more than
200 biochemical and cellular HTS datasets that have been per-
formed at Novartis over the past decade (Petrone et al., 2012).
In this approach, a screening pattern (so called HTS fingerprints;
HTS-FP) capturing the activity for all molecules across this large
assay panel is derived (Figure 2A). With this information in hand,
the Novartis pre-plated compound archive is prioritized so that
compound plate sets are assembled to represent as many distinct
screening patterns as possible (Petrone et al., 2012). A similar
route was taken in the assembly of a mechanistic diversity set
from compounds tested in the NCI60 cancer cell line panel that
was selected to cover a broad range of growth inhibition patterns
(Monga and Sausville, 2002)3 .
The second biodiversity selection approach employed at
Novartis (Petrone et al., 2013) uses bioactivity data found in
internal and external bioactivity databases (see Table S1). All pre-
plated compounds are annotated with their protein targets from
concentration-response measurements using a defined activity
threshold (typically AC50 ≤ 5μM). After curation of compound-
target interactions, the number of different targets modulated by
the compounds on a plate is counted (Figure 2B). Constraints on
compound sets can be made so that plates with a high coverage
of different targets are prioritized for screening while plates with
redundant target space coverage are removed from the set.
Interestingly, benchmark calculations comparing the efficiency
of chemical and biological diversity methods for plate-based
selection of 250,000 small molecules concluded that chemical
diversity is a necessary, but not sufficient condition for the suc-
cess of a screening library (Petrone et al., 2013). By contrast,
compound sets that were both chemically and biologically diverse
achieved the highest hit rates across a number of biochemical and
cellular screens (Petrone et al., 2013). In particular, compound
libraries selected based on known compound-target interactions
extracted from bioactivity databases achieved the best results. It
should be noted that different assumptions are made for the suc-
cess of such a biodiverse library in biochemical and phenotypic
screens. The success of a biodiverse library for a biochemical
screen can be explained by the hypothesis that compounds that
were previously found to be active are more “hit-like” than other
molecules and are therefore more likely to show bioactivity in
3 http://www.dtp.nci.nih.gov/branches/dscb/mechanistic_explanation.html
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery July 2014 | Volume 5 | Article 164 | 4
Wassermann et al. Applications of focused libraries
FIGURE 2 | Shown are two different approaches developed at Novartis
for the design of biodiverse compound libraries from a pre-plated
screening deck. (A) For each compound in the Novartis screening collection,
primary assay data from more than 200 HTS campaigns are collected,
standardized in form of z-scores, and stored in a minable activity pattern
(HTS-FP). This requires construction of a robust bioassay ontology and
curation of compound and assay information. Then compounds are clustered
by their activity patterns and screening plates are ranked in descending order
of the number of different bioactivity clusters covered by the compounds
contained in each plate. The more clusters are found on a plate, the more
dissimilar the plated compounds are with respect to their bioactivity patterns
and the higher the biodiversity of the plate. Therefore, plates from the top of
the ranking are selected for screening (unless their cluster composition is
redundant with higher ranked plates). (B) For each compound in the Novartis
screening collection, concentration-response data is extracted from curated
internal and external structure-activity databases. Compounds on a plate are
annotated with their known targets and the biodiversity of a plate is
measured by the number of different protein targets known to be modulated
by the compounds on the plate. After ranking of the plates according to their
biodiversity, the selection process is analogous to (A).
future screens against novel targets. In this case, the frequently
observed polypharmacology of small molecules is exploited. For
phenotypic screens, a second target activity is not even required
for a positive activity outcome but the already known target activ-
ity could lead to the desired phenotypic effect. In fact, screening of
a biologically annotated compound library can help to overcome
one of the major bottlenecks in drug discovery: target elucida-
tion of a hit list from a phenotypic screening campaign. By using
the known annotations of screened compounds, targets that are
enriched among the active molecules can be inferred. Likewise,
the target annotation of a small molecule can be used to link a
compound to a molecular process or pathway in which this tar-
get plays a role and processes/pathways that are overrepresented
for the hit set can be detected. This enrichment analysis leads to
a better mechanistic understanding of the phenotypic screen and
can directly be applied in hit triaging to select compounds with a
desirable mechanism of action (MoA) for follow-up assays while
removing compounds with an unwanted MoA, e.g., the inhibi-
tion of a target that is known to show broad cell cytotoxicity. Such
an understanding can help anticipate assays in the discovery flow
chart so that the appropriate counterscreens and secondary assays
are made available to follow-up active compounds.
HYPOTHESIS-DRIVEN PHENOTYPIC SCREENING LIBRARIES
Earlier in this article biologically and chemically diverse screening
sets were described as adequate libraries for phenotypic screen-
ing if no assumption about the molecular processes captured
by the phenotypic screen is made. However, if prior knowledge
about the biological model under study exists, e.g., through a
pilot screen with a compound library or literature mining, it is
often advisable to customize the screening library. Data reposito-
ries such as OMIM (Amberger et al., 2011), Gene Ontology (Blake
et al., 2013), GeneGo Metabase, and KEGG Pathways (Kanehisa
et al., 2014) can be used to establish connections between diseases,
molecular functions, processes, pathways, and involved protein
targets. In turn, public and commercial bioactivity databases
such as ChEMBL (Gaulton et al., 2012), DrugBank (Law et al.,
2014), and PubChem BioAssays (Wang et al., 2014) are a rich
resource for linking these presumably relevant targets to small
molecules thereby enabling hypothesis-driven compound cherry-
picking for phenotypic screening. An overview about bioinfor-
matics and cheminformatics resources that can be exploited for
the design of focused phenotypic screening libraries is given in
Table S1.
Although biologically annotating small molecule collections is
simple in theory and concept and the resources mentioned in
Table S1 are easily accessed, one has to consider several difficul-
ties which are often encountered when accessing these databases.
These issues mainly stem from errors in the databases and
the difficulty of obtaining unified representations of compound
structures and protein targets used by different data reposito-
ries. Multiple studies published by Kramer and colleagues have
investigated sources of compound bioactivity database errors
and the experimental uncertainty associated with published Ki
and IC50 values (Kramer and Lewis, 2012; Kramer et al., 2012;
Kalliokoski et al., 2013). Kramer and Lewis (2012) discovered
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copy-and-paste errors introduced upon transcription of activ-
ity data from original literature to databases include incorrectly
reported units (e.g., a protein-target interaction is reported with
a potency of 30 nM in the database although the underlying pub-
lication reported a potency of 30μM) and a wrong extraction
of the target protein (e.g., confusion of different receptor sub-
types or omission of the receptor subtype information in the
database). Moreover, compound structures are often incorrectly
assigned, with a predominance of stereochemistry errors. As
well, compound-target interactions that were formally correctly
extracted from the literature cannot all be considered equally
reliable. For example, determination of IC50 values depends on
the assay conditions and a compound reported as highly active
against a target by one laboratory may show weak activity in
another laboratory depending on the choice of substrate, con-
centration, and other parameters that were used in the exper-
imental design. At least for enzyme assays there are initiatives
in place to help standardize the reporting of enzyme activity
and inhibition data such as STRENDA (Standards for Reporting
Enzymology Data) (Auld and Acker, 2014; Tipton et al., 2014).
However, cell-based assays tailored toward a specific protein tar-
get are often more difficult to interpret and it is always possible
that the observed activity results from an off-target process.
Nevertheless, in a database, the assay result is often reported as
the activity of the compound against one defined protein tar-
get although the binding event has not yet been established.
Therefore, detailed knowledge of the assay protocol is often nec-
essary to judge the quality of the reported compound activity.
However, assay descriptions are often not provided by databases
or, if they are available, are in free-text format, which is difficult
to interpret and mine for large-scale annotations of compound
collections. An initiative that tries to address this problem is the
BARD4 (BioAssay Research Database) project that uses standard-
ized terms to describe experimental contexts and corresponding
result data (De Souza et al., 2014). The ChEMBL database uses
scores that are created during the manual curation process of the
data and which reflect the confidence that the correct protein tar-
get has been assigned for the reported assay. Robustly curated
compound activity databases, i.e., data quality and not necessar-
ily data quantity, will be crucial for mining and interpretation of
phenotypic screening results. Also, users of databases should be
wary of the wealth of bioactivity data that is available and criti-
cally consider these potential pitfalls and the quality level of the
reported results.
Another challenge faced by researchers using different sources
of biological annotation is data integration. As detailed in
Table S1, a multitude of informative data repositories exist, how-
ever, linking compounds or protein targets in one database to
another is a non-trivial task due to the usage of different com-
pound and target representations. For example, small molecules
might be registered in a database by SMILES (Weininger, 1988),
InChI keys (Heller et al., 2013), or CAS numbers and proteins
by UNIPROT (Uniprot, 2010), Ensembl (Flicek et al., 2011),
or Entrez gene (Maglott et al., 2011) identifiers. Therefore,
data from different repositories needs to be unified to enable
4 https://bard.nih.gov/BARD/
cross-links and a full leverage of available data. Whereas solu-
tions for data integration have been found by pharmaceutical
companies that often combine data from various internal and
external sources in one data warehouse, data access is typi-
cally more difficult for smaller academic labs that do not have
the same resources for data management and less informatics
support.
Not only biological annotations but also the chemical struc-
tures of hits can be exploited to expand around results
from a library screen employing a phenotypic assay. Even if
the targets of phenotypic screening hits are not known, it
has been shown that it is possible to learn physicochemical
properties and/or structural features from these active com-
pounds that can be used to develop new compound sets that
are likely to show the same phenotype. For example, tak-
ing data from a yeast growth inhibition screen, Wallace et al.
(2011) trained a Naïve Bayes model to distinguish substruc-
tures found within active and inactive compound sets. Focused
compound sets chosen with this model were 2 to 4-fold
enriched with phenotype-inducing compounds. Interestingly,
growth inhibitory effects of these compounds were not restricted
to yeast as the model was successfully applied to enrich
focus libraries with active compounds across diverse model
organisms.
Hypothesis-driven focused sets aimed at a particular pheno-
type can be very enabling to phenotypic assays that often involve
difficult protocols and precious cell samples such as co-culture
and 3D-culture systems employing primary cells. With increased
effort tomove tomore disease relevant phenotypic assays employ-
ing the use of precious biological samples, the design of focus
libraries to efficiently screen these assays becomes paramount.
The results from focus library testing can enable a hypothesis
related to the underlying biological mechanism of the pheno-
typic response and anticipation of the necessary secondary assays
required to test the hypothesis.
EXAMPLE TOOL COMPOUND AND PROBE LIBRARIES
The types of compounds described in the first section of this
review can be employed to construct focus libraries which are
applied to understand and characterize biological assays. Over
the past years, many efforts have been geared toward the design
of explicit tool compound or probe libraries, i.e., small molecule
libraries assembled to perturb and investigate pathways and sig-
naling cascades in phenotypic assays. These libraries are often
tested in a pilot screen before running an assay on a larger
screening deck, either with the purpose to validate the assay
(i.e., to test whether compounds that are expected to be active
based on their known MoA show up as hits) or to gain a
better mechanistic understanding of the activity arising from
phenotypic assays. This means that, through their design, these
compound sets enable MoA hypothesis formulations and the
identification of targets involved in a biological model. Typically,
these libraries consist of <10,000 low molecular weight com-
pounds covering diverse biological activities. If possible care is
taken that multiple compounds modulate the same target: if all
compounds with a common MoA evoke the same phenotypic
effect, confidence is increased that this phenotypic activity is
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related to their shared target and not the result of an unknown
off-target effect. One example of such a compound set is the
Library of Pharmacologically Active Compounds5 (LOPAC)
marketed by Sigma Aldrich. This library currently containing
1,280 compounds is largely composed of drugs and therefore has
some limitations for MoA analysis as noted previously includ-
ing an over-representation of well explored target classes such
as GPCRs and protein kinases. However, the LOPAC collection
was recently used to study lymphangiogenetic sprouting in a 3D
assay, identifying MEK 1/2 inhibitors and also the drug class of
statins that inhibit the enzyme HMG-CoA reductase as blockers
of lymphangiogenesis (Schulz et al., 2012). Similarly, the Target
Discovery Institute (TDI) at the University of Oxford is currently
constructing the TDI Small Molecular Probe Library which is
described as a collection of 3000–4000 compounds “chosen to
explore complex diseases pathways and to assist in the characteri-
zation of disease targets”6. GlaxoSmithKline (GSK) has assembled
a tool box of about 6000 compounds termed Biologically Diverse
Compound Set (BDCS) that targets 736 unique proteins (Liu
et al., 2014). Up to 10 maximally selective compounds from dif-
ferent chemical series are included for each target. The compound
set was tested for suppression or enhancement of histone-3 K27
tri-methylation (H3K27me3). In addition to compounds target-
ing methyltransferases or demethylases, a number of compounds
without direct activities against these targets were identified and
suggested to be upstream pathway regulators (Liu et al., 2014).
Mapping the compounds’ protein targets back to pathways led
to the observation that the ErbB2-ErB3 signaling pathway was
significantly overrepresented among the targets of active com-
pounds, implying an involvement of this pathway in H3K27me3
regulation. Many target-oriented libraries are available for his-
torical drug classes such as GPCRs and kinases. The kinase
inhibitor set from GSK (Dranchak et al., 2013) contains over
300 kinase inhibitors and can be used to test an assay’s sensitiv-
ity/response to particular kinases and build pathway hypotheses.
All focus libraries of bioactive compounds are best screened in
a concentration-response mode as these libraries will often have
high hit rates (>10%). Titration-based screening of pilot libraries
in a quantitative HTS (qHTS) format can provide robust potency
and efficacy data to construct target/pathway hypothesis as well
as typical assay performance statistics such as Z-factors (Inglese
et al., 2006; Zhang et al., 2013).
CONSIDERATIONS ON COMPOUND PROPERTIES
One aspect that is not further discussed in this article is that phe-
notypic screening also puts constraints on the physicochemical
properties of small molecules. In many cases, high cellular per-
meability is crucial for a compound to be active in a phenotypic
screen. Therefore, phenotypic screening libraries are optimally
designed with consideration of compound solubility and cell pen-





Furthermore, compound structures with known cytotoxic fea-
tures were removed from this screening collection.
ANALYSIS AND INTERPRETATION OF ANNOTATED
CHEMICAL LIBRARY DATA
For any assay result one needs to investigate the origins of com-
pound activity, or lack thereof, with a consideration of compound
properties as possible factors that may confound the observed
results. Research aimed at understanding assay artifacts has led
to an understanding of common chemotypes that can skew the
results arising from certain assay technologies (Thorne et al.,
2010). A number of profile studies have been performed to deter-
mine the types of compounds that form colloidal aggregates
(Feng et al., 2007; Owen et al., 2014), interfere with common flu-
orophores through compound autofluorescence (Simeonov et al.,
2008), show pan assay interference (Baell and Holloway, 2010),
interfere through redox mechanisms (Johnston et al., 2008), and
those that inhibit and stabilize reporter gene enzymes in cells
(Thorne et al., 2012; Ho et al., 2013). With this in mind, focus sets
can be designed to measure an assay’s susceptibility to artifacts
and this knowledge can then be used to anticipate the neces-
sary counterscreens. For example, the GSK kinase inhibitor set
has been screened against firefly and Renilla reniformis luciferases
because these are common reporter enzymes used to construct
assays (Dranchak et al., 2013). Such an analysis should always
be performed before using chemical library screening data for
bioactivity analysis.
In addition to taking compound interference and chemical
properties into consideration during the analysis of phenotypic
screens, it is also important to understand how such focus library
screens can be better interpreted. For example, unlike random
screening, the expected hit rate in a focus set should be high
as by design the compounds have been selected based on some
prior knowledge (e.g., they target proteins in a pathway involved
in the disease or phenotype of interest). Secondly, the defini-
tion of a “hit” is less clear as phenotypic screens measure a
biological outcome that can result from the perturbation of dif-
ferent biological processes in the cell with varying degrees of
potency. In biochemical target-based assay systems, high potency
is a reasonable way to select actives. Conversely, when using cell-
based/phenotypic assays, this approach, although still useful, can
be problematic. This is because when screening a large collection
of compounds that target different cellular processes, one may
observe a large effect on the phenotype by compounds that simply
target generic cellular mechanisms (e.g., cell-health related mech-
anisms, Figure 3) which, although these have genuine biological
activity, are less interesting or non-specific. For example, it may
be no surprise that HDAC inhibitors score in an assay that mea-
sures transcription (e.g., an RGA) or that proteasome inhibitors
would have a strong effect on assays that measure protein pro-
duction. Additionally, focusing on the strongest hits may result in
missing compounds that effect specific nodes of a relevant path-
way but have smaller effects in the assay. The smaller effect of such
compounds can be attributed to several reasons: (1) position of
the target on the pathway where compensatory mechanisms and
pathway cross-talk may result in a minor perturbation of the phe-
notype; (2) lack of uniformity in the specificity and potency of
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FIGURE 3 | Analysis of the entire bioactivity dataset. Examining
biological annotations for the entire dataset including activity outside the
extremes can rescue weak activity. (A) Depicted are three cases where
compounds modulate cell signaling. In case 1, a compound shows high
activity through, for example, activation of apoptosis. In case 2, three
compounds are annotated to targets known to function in the same
signaling pathway but each compound shows weak activity in the assay.
In case 3, a compound shows strong activity in the assay acting through
inhibition of general mechanisms such as transcription/translation. (B)
While compounds in case 1 and 3 are easily captured using standard
statistical thresholds, compounds in case 2 may only be rescued by
examining the entire dataset and considering the target annotations in
the context of biological pathway analysis. (C) Plot representing the
aggregate effect of compounds perturbing a pathway to identify weakly
active compounds (case 2). Each circle on the plot represents a pathway.
The x-axis represents the aggregate effect of compounds hitting targets
from the same pathway. For example, case 2 is depicted as having three
compounds that individually show weak activity but are annotated as
operating in the same pathway. The likelihood of getting such a score by
chance, given the number of genes/proteins, is given on the y-axis (given
as −log10, e.g., p = 0.01,2). Using such an approach, relevant biological
processes with subtle effects can be identified.
compounds; (3) lack of uniform chemical properties across the
library (cell permeability; binding kinetics), and (4) lack of con-
gruence between the time required to observe a phenotypic effect
by perturbing a given target vis-à-vis the duration of the screen.
Therefore, the interpretation of phenotypic screens should take
full advantage of prior biological knowledge, such as target and
pathways, to facilitate analysis.
Compounds that modulate upstream nodes in a pathway may
have much smaller effects on the assay signal but these weak
hits could be rescued by considering if their target annotations
place them in the same pathway (Figure 3). In this way the
entire dataset can be considered independent of potency or activ-
ity threshold values and weak activity can be considered if this
activity significantly clusters within specific pathways (Figure 3)
(Subramanian et al., 2005; Levine et al., 2006). In other words, the
aggregate effect on a biological pathway level is of highest interest
as opposed to individual compound activities. Such an analy-
sis enables: (1) identification of mechanisms of interest: known
or unknown pathways; (2) identification of new biological end-
points to help validate the observation (e.g., a pharmacodynamic
marker for a given biological process); (3) selection of compounds
that would help validate the hypothesis; and (4) rescuing weaker
but biologically relevant compounds.
The use of prior biological knowledge is particularly pow-
erful when screening with focused libraries where the MoA of
compounds is known. The identification of novel pathways and
processes can help establish additional endpoints to be measured
in a screening funnel or be used as surrogate readouts—ones
that correlate with the phenotype of interest—and that may be
more amenable to a large scale HTS campaign thus enabling
access to a much larger chemical space. For example, if in a given
focused library screen, perturbing the JNK pathway has a signif-
icant outcome in the measured phenotype, then PD biomarkers
within the JNK pathway can be selected as orthogonal measure-
ments in a screening funnel. Alternatively, such an observation
can be used to help validate the screen due to prior knowl-
edge that the JNK pathway is implicated in the biology being
measured. Ultimately, the success of any screen depends on the
interpretability of the results where the combination of a good
compound collection, measuring the right biological endpoints,
and application of analytical approaches will increase the chances
of identifying biologically relevant leads, particularly if challenges
such as polypharmacology and pleiotropic effects ofmolecules are
addressed and taken into consideration.
CHALLENGES AND FUTURE DIRECTIONS/OPPORTUNITIES
More and more evidence points to the fact that drugs previ-
ously perceived to be selective actually exert their effect through
more than one target (Hopkins, 2008; Reddy and Zhang, 2013).
Furthermore, with the advent of genomic technologies such as
gene expression profiling, it has become evident that even drugs
with high target selectivity have pleiotropic effects by modulating
diverse downstream signaling events (Lamb, 2007; Dobbelstein
and Moll, 2014). Such effects could contribute to efficacy and/or
adverse events. This has led to a shift from SAR analysis based on
a single endpoint to modeling of multiple target activities (Lopez-
Vallejo et al., 2012; Petrone et al., 2012; Medina-Franco et al.,
2013) and also to the identification of compound relationships
based on their effect on a biological system as measured by gene
expression (Lamb, 2007). Therefore, the design and interpreta-
tion of focused libraries is shifting to include a combination of
computational approaches that merge chemo-informatics, bioin-
formatics, and systems biology.
Polypharmacology presents a challenge in the interpretation
of phenotypic screens because it is not necessarily evident which
target is contributing to the effect. Furthermore, screening usu-
ally takes place at high concentrations, e.g., 10–20μM. If the
library contains both optimized bioactive molecules and also
blunt scaffolds, screening at such high concentrations favors the
polypharmacology of the optimizedmolecules to be in full display
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making the results hard to interpret. This is another reason
that a titration-based screening approach should be used when
employing MoA libraries, as mentioned above.
Polypharmacology can be established a priori by both experi-
mental and computational approaches. Experimentally, biochem-
ical profiling of target classes can give an idea of the selectivity
profile for a given molecule. Similarly, gene expression profil-
ing of compounds can shed light on the processes regulated by
the bioactive molecules. Computational approaches to establish
polypharmacology of compounds have been developed employ-
ing either properties of the ligand or the structure of the targets
(Houghten et al., 2006, 2008; Hopkins, 2008; Weill and Rognan,
2009; Renner et al., 2011). In addition, by combining gene expres-
sion and protein interaction networks, systems biology based
methods are also employed to reverse engineer the upstream tar-
gets that best explain the gene expression profile (i.e., pleiotropic
effects of a compound; Jaeger et al., 2014). All of this information
can then be leveraged to increase the interpretation of the screen
as, for example, through pathway-based methods as described
above. In addition, the polypharmacology of drugs can be used
in the rational design of focused libraries. Because kinases par-
ticipate in many different signaling pathways, one could design
a library containing kinase inhibitors that have distinct and/or
different degrees of overlapping polypharmacology to act as sen-
tinels for pathways. If the polypharmacology is known, either
through computational or experimental methods, it may then be
possible to de-convolute the result into the likely targets/pathways
involved in the phenotype. For example, Gujral et al. (2014)
identified kinases involved in the regulation of cancer cells by
exploiting diverse pharmacology of kinase inhibitors whereas
Houghten et al. (2006) have developed de-convoluting methods
for compound mixtures in in vivo screens.
CONCLUSIONS
The composition and applications of compound libraries is evolv-
ing significantly. Large archives containing analogs for known
target classes (e.g., kinases, GPCRs), combinatorial collections,
purified natural products, and diversity oriented synthesis usually
employed in large scale HTS-campaigns can now be optimized
by selecting a subset of compounds that maximize both bio-
logical and chemical diversity. More recently, largely due to the
increased use of complicated phenotypic screens—usually lim-
ited in throughput and interpretability—smaller libraries will
need to be compiled that leverage prior biological knowledge and
the polypharmacology and pleiotropism of the compounds. For
example, many ex vivo assays such as long-term potentiation or
multi-electrode arrays can be employed as phenotypic assays that
measure neuronal activity but these assays have extremely low
throughput (Thomas et al., 1972; Bliss et al., 2004). Improved
strategies to build such libraries coordinated with the devel-
opment of computational methods to interpret the results are
needed.
The ever growing body of orthogonal chemical biology
datasets will continue to change our understanding of com-
pound properties and how compounds are selected for focus
library development. For example, biological profiling may help
identify molecule classes, which although chemically distinct,
have a common biological mechanism and provide a means
for compound repositioning or an understanding of adverse
effects (Lounkine et al., 2012). Similarly, systematic efforts to
understand the toxicity of compounds have resulted in large
publicly available datasets with noted examples including data
sets from Iconix Biosciences (Ganter et al., 2005), the National
Institute of Biomedical Innovation (NIBIO, Japan) (Uehara et al.,
2010), and ToxCast released from the Environmental Protection
Agency (Chen et al., 2012; Kavlock et al., 2012; Knudsen et al.,
2013). Optimal employment of these databases requires expert
teams of biologists, chemists, and informatics scientists with
critical consideration of the source data. However, the combi-
nation of historical and ongoing chemical profiling (PubChem,
ChembL) with improved annotation and data mining tools (such
as BARD) will lead to improved methods to design focused
libraries.
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